mirdametinib for Cancer

Recruiting · 18+ · All Sexes · Santa Monica, CA

This study is evaluating whether a combination of two drugs may help treat tumors.

See full description

About the trial for Cancer

Eligible Conditions
Neoplasms · Solid Tumors, Adult

Treatment Groups

This trial involves 4 different treatments. Mirdametinib is the primary treatment being studied. Participants will be divided into 4 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.

Experimental Group 1
Experimental Group 2
Experimental Group 3
Show More


This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
during or after one prior line of therapy Cancers that have spread to other parts of the body and can't be surgically removed, and have gotten worse after at least one previous treatment course, are considered to have advanced or metastatic cancer. show original
The individual must have archival tumor tissue or agree to tumor biopsy. show original
The life expectancy of a fetus is greater than 12 weeks at the time of signing ICF. show original
The types of cancer that are included in the study are non-small cell lung cancer (NSCLC), colorectal cancer (CRC), ovarian cancer, endometrial cancer, thyroid cancer, melanoma, pancreatic cancer, and other cancers. show original
The patient must have adequate organ function and not need a transfusion within 14 days of the first dose of the medication. show original
The text discusses a certain measure of disease show original
This means that the person has difficulty performing basic activities due to cancer. show original
View All
Odds of Eligibility
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Approximately 2 years from date of the participants enrollment
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Approximately 2 years from date of the participants enrollment.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether mirdametinib will improve 3 primary outcomes in patients with Cancer. Measurement will happen over the course of Approximately 2 years from date of the participants enrollment.

Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in participants with selected tumor types
The incidence of DLT events and treatment-emergent AEs (TEAEs)
Adverse Events and Serious Adverse Events
Incidence and severity of AEs and SAEs and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is cancer?

Oncology is the study of human cancer. Cancer is the uncontrolled growth or spread of cells with a malignant potential in a human host, and is most often caused by abnormal DNA and protein functions. There are many forms of cancer, including sarcoma, leukaemia, brain tumours, and carcinoid tumor. The number of new cancer cases is increasing. There continue to be thousands of cancer deaths every year, often in developed countries.

Anonymous Patient Answer

Can cancer be cured?

Cancer can not be cured. However, with improvements in treatment options, patients with advanced cancer can have a high quality of life, with prolonged time in a relatively painless state.

Anonymous Patient Answer

What are the signs of cancer?

There is a wide variety of cancer signs, ranging from sudden illnesses, changes in appearance, and pain. Although most cancer signs are nonspecific and can suggest other diseases, some symptoms and signs may be specific to a particular type of cancer and can help to identify specific cancer types (cancers that tend to be the cause of these signs and symptoms).\n

Anonymous Patient Answer

How many people get cancer a year in the United States?

Approximately one-third of the people who are diagnosed with cancer die before the time of diagnosis, and there are nearly 500,000 people who live with metastatic cancer after their diagnosis.

Anonymous Patient Answer

What are common treatments for cancer?

Many commonly practiced therapies for cancer have no evidence of effectiveness in reducing, stabilizing, or improving symptoms, and may result in harm. These include many herbal preparations, some prescription and over-the-counter drugs, some exercise modalities, and many alternative therapies. The evidence for the effectiveness of complementary and alternative medicine in cancer treatment requires verification by well-designed clinical studies. There is an urgent need to identify and evaluate treatments that do not seem to be dangerous but do not seem to be of any use in the treatment of cancer.

Anonymous Patient Answer

What causes cancer?

Genetic and environmental influences interact to increase the risk of cancer. There is general doubt as to the role of many risk factors, though certain occupational risk factors, such as exposure to pesticides, tobacco and asbestos, are unquestionably related to the development of cancer. Cancer is a result of evolution as organisms are constantly confronted with new environmental pressures. The prevention of cancer is a topic of considerable interest, and considerable progress seems to be being made.

Anonymous Patient Answer

Have there been other clinical trials involving mirdametinib?

The first ORM-214084 phase III trial (SarcomaCure) is in its final stages of completion and is anticipated to provide more information regarding mirdametinib. Data from a recent study of this trial will not be known for some time.

Anonymous Patient Answer

Is mirdametinib safe for people?

Dose adjustment was necessary in ≥ 10% of people but is achievable, even if dose adjustments were needed frequently. Dosage increased during dose escalation. The most common adverse effects at doses up to 40 mg in Caucasian patients were gastrointestinal symptoms and fatigue. At doses up to 40 mg, myelosuppression was common in Asian patients. Dose-limiting cardiac toxicity was not observed in Caucasian and Asian patients. For unknown reasons, the incidence of diarrhoea increases significantly from 20 to 80 mg. This is the first assessment of toxicity in Asian and Mexican patients.

Anonymous Patient Answer

Have there been any new discoveries for treating cancer?

There are many advances that treat various types of cancer, most importantly, using radiation on and radiation-free radiotherapy on oncologic tumors. There are also some medicines used to treat cancer that are not yet approved for treating cancer by the US Food and Drug Administration’s Center for Disease Control and Prevention. Unfortunately, many of the medicines used to treat cancer are still in clinical trials and more research will be helpful to understand how treatment treatments works. The American Cancer Society’s National Breast Cancer Coalition (NBCC) is there to help people fight off cancer. Since this outbreak, there has been a new invention that would treat and cure cancer by focusing on the T-cells.

Anonymous Patient Answer

Is mirdametinib typically used in combination with any other treatments?

The median overall survival of patients treated with mirdametinib plus chemotherapy was 22.9 weeks. Patients treated with monotherapy showed median overall survival of 5.0-7.4 weeks. For patients who received chemotherapy before receiving mirdametinib, the median overall survival was 6.3-10.3 weeks.

Anonymous Patient Answer

Has mirdametinib proven to be more effective than a placebo?

Mirdeadinetib proved to be significantly more effective than placebo. However, further, well-designed, randomized, controlled, multicenter clinical trials are needed to assess the full efficacy of this drug.

Anonymous Patient Answer

Does cancer run in families?

The evidence suggests [breast cancer](, and all types of cancer, are largely heritable. In a recent study, findings provide a valuable resource for clinicians and researchers by allowing them to identify individuals that may have a significant increased risk of developing cancer.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cancer by sharing your contact details with the study coordinator.